Skip to main content

Phesgo

NDC 50242-260 · Genentech, Inc.

Generic namepertuzumab, trastuzumab, and hyaluronidase-zzxf
Dosage formINJECTION, SOLUTION
RouteSUBCUTANEOUS
Active ingredient(s)PERTUZUMAB, TRASTUZUMAB, HYALURONIDASE (HUMAN RECOMBINANT)
Strength20000; 600; 600 U/10mL; mg/10mL; mg/10mL
Pharmacologic classEndoglycosidase [EPC], Glycoside Hydrolases [CS], HER2/Neu/cerbB2 Antagonists [MoA], HER2/Neu/cerbB2 Antagonists [MoA], HER2/neu Receptor Antagonist [EPC], HER2/neu Receptor Antagonist [EPC]
Marketing categoryBLA

Packages

50242-260-01 — 1 VIAL, SINGLE-DOSE in 1 CARTON (50242-260-01) / 10 mL in 1 VIAL, SINGLE-DOSE

50242-260-86 — 1 VIAL, SINGLE-DOSE in 1 CARTON (50242-260-86) / 10 mL in 1 VIAL, SINGLE-DOSE

Billed under HCPCS

J9316 — Injection, pertuzumab, trastuzumab, and hyaluronidase-zzxf, per 10 mg Medicare Part B payment limit (ASP + 6%): $59.90

Related Codes

Same active ingredient

FDA lists these products with the same active ingredient.

0003-3120 — nivolumab and hyaluronidase-nvhy, 0003-6120 — nivolumab and hyaluronidase-nvhy, 0069-0308 — trastuzumab-qyyp, 18657-117 — Hyaluronidase, 50242-077 — Trastuzumab and hyaluronidase-oysk, 50242-108 — rituximab and hyaluronidase, 50242-109 — rituximab and hyaluronidase, 50242-132 — Trastuzumab, 50242-145 — Pertuzumab, 50242-245 — pertuzumab, trastuzumab, and hyaluronidase-zzxf, 50242-554 — ocrelizumab and hyaluronidase, 50242-933 — atezolizumab and hyaluronidase-tqjs, 51662-1555 — HYALURONIDASE, 55513-132 — trastuzumab-anns, 55513-141 — trastuzumab-anns, 57894-503 — daratumumab and hyaluronidase-fihj (human recombinant), 57894-510 — AMIVANTAMAB and HYALURONIDASE-lpuj (HUMAN RECOMBINANT), 57894-514 — AMIVANTAMAB and HYALURONIDASE-lpuj (HUMAN RECOMBINANT), 57894-515 — AMIVANTAMAB and HYALURONIDASE-lpuj (HUMAN RECOMBINANT), 57894-522 — AMIVANTAMAB and HYALURONIDASE-lpuj (HUMAN RECOMBINANT), +7 more

From the FDA National Drug Code Directory, retrieved August 24, 2026. Product listings are submitted by labelers; FDA does not verify them.

Read from: FDA National Drug Code Directory, product.txt and package.txt (accessdata.fda.gov/cder/ndctext.zip) — Snapshot retrieved 2026-08-24, loaded 2026-08-24; CMS Medicare Part B Drug Average Sales Price (ASP) Pricing Files (cms.gov/medicare/payment/part-b-drugs/asp-pricing-files) -- the NDC-HCPCS crosswalk and Part B payment limit files — 2026 Q3 (July 2026 release). All data sources · How to read the labels